Evidence map›Paper›PMID 40488253›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Diverse tau pathologies in late-life mood disorders revealed by PET and autopsy assays.

Shin Kurose, Sho Moriguchi, Manabu Kubota, Kenji Tagai, Yuki Momota, Masanori Ichihashi, Yasunori Sano, Hironobu Endo, Kosei Hirata, Yuko Kataoka and 20 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Diverse tau pathologies in late-life mood disorders revealed by PET and autopsy assays.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Shin KuroseAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.ORCID 0000-0001-8355-4946
Sho MoriguchiAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Manabu KubotaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Kenji TagaiAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Yuki MomotaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Masanori IchihashiAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Yasunori SanoDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Hironobu EndoAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Kosei HirataAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Yuko KataokaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Ryoji GotoAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Yuki MashimaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Yasuharu YamamotoAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Hisaomi SuzukiDepartment of Psychiatry, National Hospital Organization Shimofusa Psychiatric Medical Center, Chiba, Japan.
Shinichiro NakajimaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Masashi MizutaniDepartment of Clinical Laboratory, National Center of Neurology and Psychiatry, Tokyo, Japan.
Terunori SanoDepartment of Clinical Laboratory, National Center of Neurology and Psychiatry, Tokyo, Japan.
Kazunori KawamuraDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Chiba, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Chiba, Japan.
Harutsugu TatebeAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Takahiko TokudaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Mitsumoto OnayaDepartment of Psychiatry, National Hospital Organization Shimofusa Psychiatric Medical Center, Chiba, Japan.
Masaru MimuraDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Naruhiko SaharaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Hidehiko TakahashiDepartment of Psychiatry and Behavioral Sciences, Institute of Science Tokyo, Tokyo, Japan.
Hiroyuki UchidaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Masaki TakaoDepartment of Clinical Laboratory, National Center of Neurology and Psychiatry, Tokyo, Japan.
Jeffrey H MeyerBrain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health and University of Toronto, Toronto, Ontario, Canada.
Makoto HiguchiAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Keisuke TakahataAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.ORCID 0000-0002-0884-4924

Funding

Astellas Foundation for Research on Metabolic DisordersJapan Agency for Medical Research and Development JP19dm0207072Japan Agency for Medical Research and Development JP19dm0307105Japan Agency for Medical Research and Development JP21wm0425019Japan Agency for Medical Research and Development JP22dk0207055Japan Agency for Medical Research and Development JP24wm0625001Japan Agency for Medical Research and Development JP24wm0625304Japan Agency for Medical Research and Development JP24wm0625505Japan Agency for Medical Research and Development JP24zf0127012Japan Agency for Medical Research and Development JP25fk0108707Japan Science and Technology Agency JPMJMS2024Japan Society for the Promotion of Science 20K07935Japan Society for the Promotion of Science 21K06417Japan Society for the Promotion of Science 22H02998Japan Society for the Promotion of Science 22H04923Japan Society for the Promotion of Science 23H00414Japan Society for the Promotion of Science 24K02374Japan Society for the Promotion of Science 24K02379
6 · The paper itself

Abstract

introductionLate-life mood disorders (LLMDs) may represent prodromal manifestations of neurodegenerative dementia; however, the neuropathological basis of LLMDs, including depression and bipolar disorder, remains unclear. We aimed to investigate the involvement of Alzheimer's disease (AD) and non-AD tau pathologies in LLMD participants.

methodsFifty-two LLMD participants and 47 age- and sex-matched healthy controls (HCs) underwent tau and amyloid beta (Aβ) positron emission tomography (PET) imaging using

resultsLLMD participants were more likely to be tau PET and Aβ PET positive than HCs. The PET results were supported by the post mortem results that showed a higher likelihood of diverse tauopathies in patients with late-life mania or depression than those without. DISCUSSION: Our PET and autopsy assays suggest that AD and diverse non-AD tau pathologies might underlie the neuropathological basis of some LLMD cases. HIGHLIGHTS: Late-life mood disorders (LLMDs) may represent prodromal states of dementia. The neuropathological basis of LLMDs remains unclear. LLMD subjects were highly likely to be tau positron emission tomography (PET) positive. Brain bank data supported our PET results. Alzheimer's disease (AD) and diverse non-AD tau pathologies can contribute to LLMDs.

Indexed as

BrainMood DisordersTauopathiestau ProteinsAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAutopsyFemaleHumansMalePositron-Emission TomographyAmyloid beta-Peptidestau Proteinslate‐life bipolar disorderlate‐life depressionlate‐life mood disorderpositron emission tomographypost mortem studyprodromal states of dementiatauopathy

Identifiers

PMID40488253
PMCPMC12146903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.